Apollon Wealth Management LLC Increases Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX)

Apollon Wealth Management LLC boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 38.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 6,568 shares of the medical research company’s stock after buying an additional 1,823 shares during the period. Apollon Wealth Management LLC’s holdings in Quest Diagnostics were worth $906,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Raymond James & Associates lifted its holdings in shares of Quest Diagnostics by 103.3% in the 4th quarter. Raymond James & Associates now owns 148,251 shares of the medical research company’s stock worth $20,441,000 after acquiring an additional 75,315 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new position in Quest Diagnostics in the 4th quarter valued at $1,483,000. Wellington Management Group LLP increased its stake in Quest Diagnostics by 14.6% in the 3rd quarter. Wellington Management Group LLP now owns 2,613,793 shares of the medical research company’s stock worth $318,517,000 after buying an additional 333,947 shares during the period. Pacer Advisors Inc. raised its stake in shares of Quest Diagnostics by 201.5% during the fourth quarter. Pacer Advisors Inc. now owns 31,912 shares of the medical research company’s stock valued at $4,400,000 after acquiring an additional 21,327 shares in the last quarter. Finally, Strs Ohio lifted its holdings in shares of Quest Diagnostics by 7.6% in the 4th quarter. Strs Ohio now owns 16,270 shares of the medical research company’s stock worth $2,243,000 after buying an additional 1,150 shares during the period. 88.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 661 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total transaction of $83,378.54. Following the completion of the sale, the senior vice president now directly owns 40,206 shares in the company, valued at approximately $5,071,584.84. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Quest Diagnostics news, Director Vicky B. Gregg sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $126.64, for a total value of $316,600.00. Following the completion of the transaction, the director now directly owns 16,329 shares of the company’s stock, valued at $2,067,904.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael E. Prevoznik sold 661 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total transaction of $83,378.54. Following the transaction, the senior vice president now directly owns 40,206 shares of the company’s stock, valued at $5,071,584.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,910 shares of company stock worth $2,159,602. 0.79% of the stock is owned by company insiders.

Quest Diagnostics Trading Up 1.5 %

NYSE:DGX opened at $138.16 on Friday. The company has a market capitalization of $15.35 billion, a P/E ratio of 18.59, a PEG ratio of 2.98 and a beta of 0.88. The company has a current ratio of 0.97, a quick ratio of 0.89 and a debt-to-equity ratio of 0.59. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $145.58. The firm has a fifty day simple moving average of $131.21 and a 200-day simple moving average of $132.08.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.18. The company had revenue of $2.37 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The firm’s revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.04 EPS. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on DGX. StockNews.com downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. TheStreet cut Quest Diagnostics from a “b-” rating to a “c” rating in a research note on Monday, February 5th. Barclays boosted their target price on shares of Quest Diagnostics from $138.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Citigroup lifted their price objective on shares of Quest Diagnostics from $135.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Finally, Truist Financial increased their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, April 24th. Ten investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Quest Diagnostics has a consensus rating of “Hold” and an average target price of $146.17.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.